Myriad Genetic Laboratories
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Myriad Genetic Laboratories sits in the top decile of US sponsors by registered trial count (#934 of 15,751 sponsors by registered trial count).
Myriad Genetic Laboratories: 15 sponsored US clinical trials, none currently recruiting.
Myriad Genetic Laboratories sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 3 trials.
Top-decile sponsor footprint
Myriad Genetic Laboratories ranks in the top decile of sponsors by registered trial count (#934 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894
EndoPredict® Extended Endocrine Trial (EXET)
NCT04016935
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing
NCT04015102
Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing
NCT03511235
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
NCT03290508
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes
NCT03081455
Bipolar Proteomic Assay Validation Study
NCT02746367
Combined Breast Cancer Risk Study
NCT03067389
Prospective Prolaris Value and Efficacy
NCT03152448
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
NCT02121899
Registry to Measure the Impact of Adding Genomic Testing
NCT02454595
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
NCT02209584
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
NCT02121925
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
NCT01954004
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6
NCT01468623
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
How the Myriad Genetic Laboratories archive is shaped
15 indexed studies, none listed as recruiting (0% open); 7 completed (47%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Prostate Cancer (3 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.